Generic placeholder image



ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Mini-Review Article

Remdesivir, A Potential Drug for COVID-19 Treatment: A New Hope

Author(s): Kuldeep Singh, Dilpreet Singh* and Karan Razdan

Volume 2, Issue 8, 2021

Published on: 18 December, 2020

Article ID: e260721189256 Pages: 3

DOI: 10.2174/2666796701999201218141652


Objective: Coronavirus Disease-2019 (COVID-19) is a pandemic outbreak in the world and is the leading cause of Severe Acute Respiratory Syndrome (SARS).

Methods: Currently, many drugs/therapies have been tested for COVID-19, which responded sub- -optimally to the patients. Remdesivir is an RNA polymerase inhibitor that found promising results in ongoing clinical trials and shows a faster recovery rate in COVID-19 patients. Currently, USFDA approves for emergent use of this drug in severe COVID-19 patients.

Results: In this review, we discussed a brief overview of biopharmaceutical and pharmacological aspects of Remdesivir. Moreover, the ongoing regulatory status of Remdesivir by official bodies has also been described.

Keywords: Remdesivir, COVID-19, USFDA, SARS, WHO, RNA polymerase inhibitor.

Graphical Abstract

© 2022 Bentham Science Publishers | Privacy Policy